Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 9.5× earnings vs its 5.8× historical median P/E.
Fair value ≈ $24.50 · price $40.65 today
Overvalued · 66% above
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
ALK-Abelló – Denmark's next pharma highflyer?
You are unlikely to have heard of $AKBLF, but it's a hidden champion that could yet get a lot more attention over the years to come.
The company commands a 35% global market share in immunotherapies for allergies. Just 1% of its 500m strong target market is using these therapies yet, which leaves massive potential for growth.
ALK-Abelló's share price is down 40% over the past two years. Is now the right time to add this company to your watchlist?
https://www.undervalued-shares.com/weekly-dispatches/alk-abello-denmarks-next-pharma-highflyer
$AKBLF U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents
https://www.stocktitan.net/news/AKBLF/u-s-fda-approves-alk-s-odactra-r-house-dust-mite-allergen-extract-crtk6a670g6b.html
